Selection and characterization of DNA aptamer against glucagon receptor by cell-SELEX
暂无分享,去创建一个
Ke Chen | Bo Liu | Jun Liu | Ting Fu | Wen Zhong | Ting Fu | Ke Chen | Jie Liao | Ying Pu | Huixia Liu | Weihong Tan | Jianglin Li | Xiaoxiao Hu | Xiaoxiao Hu | Y. Pu | Guodong Wang | Yiling Xu | Lei Zhu | Jianglin Li | J. Liao | Bo Liu | Jun Liu | Huixia Liu | Wen Zhong | W. Tan | Guodong Wang | Lei Zhu | Yiling Xu
[1] L. Cerchia,et al. Targeting Axl with an high-affinity inhibitory aptamer. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.
[2] John O Trent,et al. Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer. , 2009, Experimental and molecular pathology.
[3] J. Holst,et al. Glucagon antagonism as a potential therapeutic target in type 2 diabetes , 2011, Diabetes, obesity & metabolism.
[4] Katherine A. Winters,et al. Long-Term Inhibition of the Glucagon Receptor with a Monoclonal Antibody in Mice Causes Sustained Improvement in Glycemic Control, with Reversible α-Cell Hyperplasia and Hyperglucagonemia , 2009, Journal of Pharmacology and Experimental Therapeutics.
[5] D. Shangguan,et al. Generating Cell Targeting Aptamers for Nanotheranostics Using Cell-SELEX , 2016, Theranostics.
[6] A. Cherrington,et al. Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover. , 2012, The Journal of clinical investigation.
[7] Jun Liu,et al. Recent developments in protein and cell-targeted aptamer selection and applications. , 2011, Current medicinal chemistry.
[8] M. J. Charron,et al. Metabolic manifestations of insulin deficiency do not occur without glucagon action , 2012, Proceedings of the National Academy of Sciences.
[9] H. Dehghani,et al. Generation of an enriched pool of DNA aptamers for an HER2‐overexpressing cell line selected by Cell SELEX , 2011, Biotechnology and applied biochemistry.
[10] D. Shangguan,et al. Aptamer Directly Evolved from Live Cells Recognizes Membrane Bound Immunoglobin Heavy Mu Chain in Burkitt's Lymphoma Cells*S , 2007, Molecular & Cellular Proteomics.
[11] Xiaobing Zhang,et al. CD109 is identified as a potential nasopharyngeal carcinoma biomarker using aptamer selected by cell-SELEX , 2016, Oncotarget.
[12] Yoshikazu Nakamura,et al. Selection of RNA aptamers against recombinant transforming growth factor-beta type III receptor displayed on cell surface. , 2006, Biochimie.
[13] L. Gold,et al. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. , 1990, Science.
[14] N. Janjić,et al. Novel approach to specific growth factor inhibition in vivo: antagonism of platelet-derived growth factor in glomerulonephritis by aptamers. , 1999, The American journal of pathology.
[15] J. Gerich,et al. The role of alpha-cell dysregulation in fasting and postprandial hyperglycemia in type 2 diabetes and therapeutic implications. , 2007, Endocrine reviews.
[16] Zilong Zhao,et al. Nucleic acid aptamers: an emerging frontier in cancer therapy. , 2012, Chemical communications.
[17] F. Ducongé,et al. From Ugly Duckling to Swan: Unexpected Identification from Cell-SELEX of an Anti-Annexin A2 Aptamer Targeting Tumors , 2014, PloS one.
[18] B. Sullenger,et al. Aptamers: an emerging class of therapeutics. , 2005, Annual review of medicine.
[19] F J Grant,et al. Expression cloning and signaling properties of the rat glucagon receptor. , 1993, Science.
[20] N. Porksen,et al. Hepatic and glucagon-like peptide-1-mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors. , 2004, The Journal of clinical investigation.
[21] Ke Chen,et al. Exopolysaccharide from Trichoderma pseudokoningii induces macrophage activation. , 2016, Carbohydrate polymers.
[22] D. Shangguan,et al. Aptamers evolved from live cells as effective molecular probes for cancer study , 2006, Proceedings of the National Academy of Sciences.
[23] Silvia Catuogno,et al. Inhibition of receptor signaling and of glioblastoma-derived tumor growth by a novel PDGFRβ aptamer. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.
[24] L. Gold,et al. A tenascin-C aptamer identified by tumor cell SELEX: Systematic evolution of ligands by exponential enrichment , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[25] W. Duan,et al. Selection of DNA aptamers against epithelial cell adhesion molecule for cancer cell imaging and circulating tumor cell capture. , 2013, Analytical chemistry.
[26] Bo Liu,et al. Adipo8, a high-affinity DNA aptamer, can differentiate among adipocytes and inhibit intracellular lipid accumulation in vitro , 2015, Science China Chemistry.
[27] A. Consoli. Role of Liver in Pathophysiology of NIDDM , 1992, Diabetes Care.
[28] Xingmei Zhang,et al. Cell-SELEX Aptamer for Highly Specific Radionuclide Molecular Imaging of Glioblastoma In Vivo , 2014, PloS one.
[29] S. Qureshi,et al. Chronic treatment with a glucagon receptor antagonist lowers glucose and moderately raises circulating glucagon and glucagon-like peptide 1 without severe alpha cell hypertrophy in diet-induced obese mice , 2011, Diabetologia.
[30] J. Treadway,et al. Polyomic profiling reveals significant hepatic metabolic alterations in glucagon-receptor (GCGR) knockout mice: implications on anti-glucagon therapies for diabetes , 2011, BMC Genomics.
[31] Bei B. Zhang,et al. Glucagon and regulation of glucose metabolism. , 2003, American journal of physiology. Endocrinology and metabolism.
[32] D. Guyer,et al. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease , 2006, Nature Reviews Drug Discovery.
[33] Kyoung-Jin Oh,et al. Identification of DNA Aptamers toward Epithelial Cell Adhesion Molecule via Cell-SELEX , 2014, Molecules and cells.
[34] W. Tan,et al. Selection of Aptamers Specific for Adipose Tissue , 2012, PloS one.
[35] R. Burcelin,et al. Molecular and cellular aspects of the glucagon receptor: role in diabetes and metabolism. , 1996, Diabetes & metabolism.
[36] C. Yang,et al. Using DNA Aptamer Probe for Immunostaining of Cancer Frozen Tissues , 2014, Analytical chemistry.
[37] Weihong Tan,et al. Cell-specific aptamer probes for membrane protein elucidation in cancer cells. , 2008, Journal of proteome research.
[38] Silvia Catuogno,et al. Targeting Insulin Receptor with a Novel Internalizing Aptamer , 2016, Molecular therapy. Nucleic acids.
[39] S. M. Taghdisi,et al. Development of RNA aptamers as molecular probes for HER2+ breast cancer study using cell-SELEX , 2015, Iranian journal of basic medical sciences.
[40] Siqing Shan,et al. Inhibition of rat corneal angiogenesis by a nuclease-resistant RNA aptamer specific for angiopoietin-2 , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[41] Weihong Tan,et al. DNA Aptamer Selected against Pancreatic Ductal Adenocarcinoma for in vivo Imaging and Clinical Tissue Recognition , 2015, Theranostics.
[42] M. Michael,et al. Glucagon as a target for the treatment of Type 2 diabetes , 2005, Expert opinion on therapeutic targets.
[43] S. Sell,et al. A Mixed Mirror-image DNA/RNA Aptamer Inhibits Glucagon and Acutely Improves Glucose Tolerance in Models of Type 1 and Type 2 Diabetes , 2013, The Journal of Biological Chemistry.
[44] Weihong Tan,et al. Identification of Cell Membrane Protein Stress-Induced Phosphoprotein 1 as a Potential Ovarian Cancer Biomarker Using Aptamers Selected by Cell Systematic Evolution of Ligands by Exponential Enrichment , 2014, Analytical chemistry.
[45] V. Ding,et al. Discovery of potent, orally active benzimidazole glucagon receptor antagonists. , 2008, Bioorganic & medicinal chemistry letters.
[46] HighWire Press,et al. The journal of pharmacology and experimental therapeutics , 1909 .
[47] A D Ellington,et al. Aptamers as therapeutic and diagnostic reagents: problems and prospects. , 1997, Current opinion in chemical biology.
[48] D. Shangguan,et al. Development of DNA aptamers using Cell-SELEX , 2010, Nature Protocols.
[49] Katherine A. Winters,et al. Fully Human Monoclonal Antibodies Antagonizing the Glucagon Receptor Improve Glucose Homeostasis in Mice and Monkeys , 2009, Journal of Pharmacology and Experimental Therapeutics.
[50] B. Monia,et al. Reduction in glucagon receptor expression by an antisense oligonucleotide ameliorates diabetic syndrome in db/db mice. , 2004, Diabetes.
[51] B. Shen,et al. Single-stranded DNA aptamers that bind differentiated but not parental cells: subtractive systematic evolution of ligands by exponential enrichment. , 2003, Journal of biotechnology.
[52] Tao Wang,et al. RNA aptamers targeting cancer stem cell marker CD133. , 2013, Cancer letters.
[53] W. Tompson,et al. Problems and Prospects: , 2020, Jewish Christianity.
[54] D. Shangguan,et al. Facile Discovery of Cell-Surface Protein Targets of Cancer Cell Aptamers* , 2015, Molecular & Cellular Proteomics.
[55] Chun-Wei Peng,et al. Identification of an aptamer through whole cell-SELEX for targeting high metastatic liver cancers , 2016, Oncotarget.
[56] Fang Wang,et al. DNA aptamers that target human glioblastoma multiforme cells overexpressing epidermal growth factor receptor variant III in vitro , 2013, Acta Pharmacologica Sinica.
[57] Ting Fu,et al. Using aptamers to elucidate esophageal cancer clinical samples , 2015, Scientific Reports.